RenovoRx Inc Aktie News

Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath® Appointment Strengthens RenovoRx's C-Suite Leadership to Support Commercial Growth of RenovoCath®

Results Support TAMP's Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery Results Support TAMP's Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-Delivery

MOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company's RenovoCath patented FDA-cleared drug-delivery device into oncology treatment progra...

CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress CEO Shaun Bagai to Discuss RenovoRx's Commercial and Clinical Program Progress

New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx's TAMP Therapy Platform as a Targeted Drug-Delivery Approach

MOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc.

RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 Transcript